Card Care. 2012;1:291-301.
Dr. Rab is an Interventional Cardiologist at Emory
ing risk-adverse behavior that negatively impact
10. Anyfantakis ZA, Baron G, Aubry P, et al. Am Heart J.
University Hospital in Atlanta, GA, a member of the
the patients who have the most to gain from the
2009;157:312-8.
ACC Interventional Council leadership committee and
procedure. It was noted the adjusted total mortality
11. Dehmer GJ, Drozda JP, Brindis RG, et al. J Am Coll Cardiol.
a councilor of the Georgia chapter of the ACC.
2014;63:1239-45.
for patients presenting with STEMI is significantly
12. Joynt KE, Blumenthal DM, Orav E, et al. JAMA.
higher in states with public reporting compared to
Dr. McDaniel is an Interventional Cardiologist at Emory
2012;308:1460-8.
and Director of the Cardiac Catheterization Laboratory
those without public reporting.12 This may be in
13. Peberdy MA, Donnino MW, Callaway CW, et al.
at Grady Memorial Hospital in Atlanta, GA.
Circulation. 2013;128:762-773.
part related to lower utilization of angiography and
PCI in patients these patients with
STEMI (61.8% vs 68%, OR 0.73;
95% CI 0.59-0.89, p = 0.002) and
Luminous Phenomena (Phosphenes)
Monitor pregnant women with chronic heart failure in 3rd
Corlanor® (ivabradine)
trimester of pregnancy for preterm birth.
Phosphenes are phenomena described as a transiently
BRIEF SUMMARY OF PRESCRIBING INFORMATION
cardiogenic shock or cardiac arrest
enhanced brightness in a limited area of the visual field, halos,
Data
Please
see
package
insert
for
full
Prescribing
Information
image decomposition (stroboscopic or kaleidoscopic effects),
(41.5% vs 46.7%; OR 0.79; 95%
Animal Data
colored bright lights, or multiple images (retinal persistency).
1. INDICATIONS AND USAGE
In pregnant rats, oral administration of ivabradine during
CI 0.64-0.98, p = 0.03) compared
Phosphenes are usually triggered by sudden variations in
Corlanor is indicated to reduce the risk of hospitalization for
the period of organogenesis (gestation day 6-15) at doses of
light
intensity.
Corlanor
can
cause
phosphenes,
thought
to
be
worsening heart failure in patients with stable, symptomatic
2.3, 4.6, 9.3, or 19 mg/kg/day resulted in fetal toxicity and
to states that do not publicly report
mediated
through
Corlanor’s
effects
on
retinal
photoreceptors
chronic heart failure with left ventricular ejection fraction
teratogenic effects. Increased intrauterine and post-natal
[see
Clinical
Pharmacology
(12.1)].
Onset
is
generally
within
≤
35%,
who
are
in
sinus
rhythm
with
resting
heart
rate
≥
70
mortality and cardiac malformations were observed at doses
mortality outcomes. Interestingly,
the first 2 months of treatment, after which they may occur
beats per minute and either are on maximally tolerated doses
≥ 2.3 mg/kg/day (equivalent to the human exposure at the MRHD
repeatedly. Phosphenes were generally reported to be of mild to
in Massachusetts, the rates of PCI
of beta-blockers or have a contraindication to beta-blocker use.
based on AUC0-24hr). Teratogenic effects including interventricular
moderate intensity and led to treatment discontinuation in < 1%
septal defect and complex anomalies of major arteries were
4. CONTRAINDICATIONS
were similar to other non-reporting
of patients; most resolved during or after treatment.
observed at doses ≥ 4.6 mg/kg/day (approximately 3 times the
Corlanor is contraindicated in patients with:
human exposure at the MRHD based on AUC0-24hr).
6.2 Postmarketing Experienc